Major depression remains one of the leading causes of disability and suicidality worldwide. A key reason for the inadequate effectiveness of many treatments is their marked biological and clinical heterogeneity. The available evidence indicates that chronically increased inflammatory activity is a key pathophysiological mechanism in a relevant proportion of those affected. This inflammatory subgroup shows characteristic biomarker profiles, specific symptom clusters, a particular interaction with neurotransmitter systems and a differentiated response to forms of therapy. The precise characterization of this subtype can make a decisive contribution to the further development of targeted, mechanistically based personalized psychiatry.
Autoren
- Tanja Schliebe
Publikation
- Depression und Angstörungen-Special
Related Topics
You May Also Like
- Hidradenitis suppurativa: biologics reduce inflammatory processes
Treatment recommendations depend on the severity and inflammatory activity
- Dizziness as a leading symptom: new consensus paper
Current recommendations for handling in everyday practice
- Endometrial carcinoma, malignant melanoma and NSCLC in focus
Personalized mRNA and neoantigen vaccines in oncology
- Consequences for pathophysiology, clinic and therapy
The inflammatory subgroup of major depression
- Adherence of GLP1-RA
Half of patients discontinue treatment within a year
- RSV infection in adult patients at risk
Vaccination as a simple and sensible prophylaxis
- A case-based, practical overview from Canada
Vaccinations for heart patients
- Acne treatment: current trends